Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer.
about
Persistent androgen receptor addiction in castration-resistant prostate cancerHER2 Dimerization Inhibitor Pertuzumab - Mode of Action and Clinical Data in Breast CancerOpen-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative meCardio-oncology in targeting the HER receptor family: the puzzle of different cardiotoxicities of HER2 inhibitors.Glycoengineering of pertuzumab and its impact on the pharmacokinetic/pharmacodynamic properties.Safety and efficacy evaluation of pertuzumab in patients with solid tumorsEpidermal Growth Factor Receptor (EGFR) mutation analysis, gene expression profiling and EGFR protein expression in primary prostate cancer.The European Medicines Agency Review of Pertuzumab for the treatment of adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer: summary of the scientific assessment of the committee for medicinal products for huLeptin signaling and apoptotic effects in human prostate cancer cell lines.Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab.A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancerCardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with [corrected] human epidermal growth factor receptor 2-positive metastatic breast cancerConstitutive activity of the androgen receptor.Targeting ErbB3: the New RTK(id) on the Prostate Cancer Block.Castration-resistant prostate cancer: new science and therapeutic prospects.Genomic and epigenomic alterations in prostate cancer.Molecular mechanisms of cardiotoxicity induced by ErbB receptor inhibitor cancer therapeuticsTendencies for higher co-expression of EGFR and HER2 and downregulation of HER3 in prostate cancer lymph node metastases compared with corresponding primary tumors.Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancerA phase Ib study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumours.Molecular therapy in urologic oncology.Prognostic value of Her-2/neu and DNA index for progression, metastasis and prostate cancer-specific death in men with long-term follow-up after radical prostatectomyPositron emission tomography/computed tomography and radioimmunotherapy of prostate cancer.Signalling pathways in prostate carcinogenesis: potentials for molecular-targeted therapy.Mechanisms of androgen receptor activation in castration-resistant prostate cancerSmall-molecule protein tyrosine kinase inhibitors for the treatment of metastatic prostate cancer.MicroRNAs as putative mediators of treatment response in prostate cancer.Management of metastatic castration-resistant prostate cancer: recent advances.Risk of rash with the anti-HER2 dimerization antibody pertuzumab: a meta-analysis.HER dimerization inhibitors: developing pertuzumab as an anticancer agent in women's oncology.Pertuzumab : evolving therapeutic strategies in the management of HER2-overexpressing breast cancer.Pertuzumab for the treatment of metastatic breast cancer.Emerging paradigms in cardiomyopathies associated with cancer therapies.Profiling serum HER-2/NEU in prostate cancer.The level of HER2 expression is a predictor of antibody-HER2 trafficking behavior in cancer cells.Antibody targeting of HER2/HER3 signaling overcomes heregulin-induced resistance to PI3K inhibition in prostate cancer.Androgen Signaling in Prostate Cancer.Randomized Phase II trial of nintedanib, afatinib and sequential combination in castration-resistant prostate cancer.Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro.Transcriptional response profiles of paired tumor-normal samples offer novel perspectives in pan-cancer analysis.
P2860
Q26777163-1525B97A-12E1-4368-A5D7-9A1375DB4DEBQ28237833-F0573B85-381A-48FB-9D0E-BF18CEC9C648Q30376023-6C2421E1-BA81-4835-BD72-487CA6C68D40Q33352155-0ACA6985-2CE5-4337-8A19-320EC07D431DQ33551688-6B728C15-1498-4C9F-A837-DD48E4F80C47Q33714388-1C137C77-A35A-4AC2-A8FD-CC1F1B9ABC04Q33803406-45AC00A3-4329-4D82-9749-E6D0BB91BF60Q33829742-2E7077DD-D06D-4688-8995-8398C0714120Q33889654-E65B2463-3ACB-4487-B478-9FC19B1BFA5FQ33930241-E473EB38-4462-4CB5-9D2A-CBE4C8091C1BQ34051972-161FA696-3C76-47C9-A912-4ACEA22B7787Q34775370-1C40256B-EDAF-4BAE-B6F1-0BBC4ED6A043Q34775572-93E306FD-F89A-4E90-8DED-011F18D6D23CQ34985562-8E916473-C39C-48F3-A221-30FD22FF86DEQ35076264-272384DF-3ED7-4945-AACC-E24049B3C803Q36374578-8B47AEFA-9FCE-45AE-A1D4-BC04E4691E36Q36396421-1DAC6DAE-8426-47E8-B77C-69435E29D50DQ36475900-A5BE8D82-55B4-4BD9-A433-8F69FF206B9BQ36504117-D054CDFC-0D7F-4830-AC2E-305ED367431DQ36610615-66D3D03C-923C-4D4D-902C-69C20AC3A594Q36878961-5CD8358C-F6D5-47A1-B7E0-CEFF14A6F8B8Q37120344-3B13A19A-905B-470F-B753-64B4B31FD1D6Q37457888-D2E6209C-2249-43B8-A7C1-AAE98993AFDFQ37575815-F8597B30-295D-4008-9720-0C30B7576327Q37628940-975C31F3-1404-4FA1-8E39-2BEB1B1807C3Q37968256-32241539-CB86-4A9B-B51B-FF4ABD0902D8Q38011943-6E361098-119E-46F3-97EE-439708189B10Q38012528-26EEA444-CD69-457D-87D6-723432B5ECEAQ38025317-CC0E0666-3E07-4FE3-8701-EA0975B837A0Q38089883-28F0EEEA-1362-4A04-9A4B-2D4AABCC763FQ38093224-93FF4827-6577-46A6-98C1-880BCFD038BCQ38132237-A6DE2888-3D19-4A20-8B75-1D22485F3AE6Q38132645-A924AA8C-D6ED-4EF1-9334-70E4013B2D81Q38174595-1248BF66-CE0F-46CF-A38F-761D4629281AQ38927764-44A1C18B-7582-4DB2-93CE-118937506018Q38932495-6E37337B-9D03-43C9-9C79-0D75BA9CB025Q39227656-AB8C45F1-4897-4B19-A8D2-90BEFCB4990EQ39257661-B7D06CDA-B77C-436D-834B-A046A902EF3AQ39931512-F1578EC8-7C8F-423D-9A36-9FAB7035BECDQ41092592-64EA0C35-4C2D-4966-9137-0F436A57936D
P2860
Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer.
description
2007 nî lūn-bûn
@nan
2007 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Open-label phase II study eval ...... ne-refractory prostate cancer.
@ast
Open-label phase II study eval ...... ne-refractory prostate cancer.
@en
Open-label phase II study eval ...... ne-refractory prostate cancer.
@nl
type
label
Open-label phase II study eval ...... ne-refractory prostate cancer.
@ast
Open-label phase II study eval ...... ne-refractory prostate cancer.
@en
Open-label phase II study eval ...... ne-refractory prostate cancer.
@nl
prefLabel
Open-label phase II study eval ...... ne-refractory prostate cancer.
@ast
Open-label phase II study eval ...... ne-refractory prostate cancer.
@en
Open-label phase II study eval ...... ne-refractory prostate cancer.
@nl
P2093
P356
P1476
Open-label phase II study eval ...... one-refractory prostate cancer
@en
P2093
Aude Flechon
Chris Parker
Cora Sternberg
Gerhard Zugmaier
Jean Pierre Droz
Joaquim Bellmunt
Johann Sebastian de Bono
Kurt Miller
Louise Cockey
Malcolm Mason
P304
P356
10.1200/JCO.2006.07.0888
P407
P577
2007-01-01T00:00:00Z